 <h1>Rucaparib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to rucaparib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, rucaparib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking rucaparib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty in breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>muscle aches</li>
<li>nasal congestion</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>rapid weight gain</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>tingling of the hands or feet</li>
<li>trouble breathing</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>tenderness of the palms and soles</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of rucaparib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>change in taste</li>
<li>constipation</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>discouragement</li>
<li>dizziness</li>
<li>feeling sad or empty</li>
<li>heartburn</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>indigestion</li>
<li>irritability</li>
<li>itching, skin rash</li>
<li>lack of appetite</li>
<li>lack or loss of strength</li>
<li>loss of interest or pleasure</li>
<li>loss of taste</li>
<li>nausea</li>
<li>redness or other discoloration of the skin</li>
<li>severe sunburn</li>
<li>stomach discomfort, upset, or pain</li>
<li>stomach distention</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>vomiting</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rucaparib: oral tablet</i></p><h3>General</h3><p>-The most common adverse reactions reported in at least 20% of patients were nausea, asthenia/fatigue, vomiting, anemia, constipation, dysgeusia, decreased appetite, diarrhea, abdominal pain, dyspnea, and thrombocytopenia.</p>
<p>-The most common laboratory abnormalities reported in at least 35% of patients were increased creatinine, increased ALT, increased AST, decreased hemoglobin, decreased lymphocytes, increased cholesterol, decreased platelets, and decreased absolute neutrophil count.</p>
<p>-Adverse reactions led to dose reduction or interruption in 62% of patients (most frequently from anemia [27%] and asthenia/fatigue [22%]), and to dose discontinuation in 10% of patients (most frequently from asthenia/fatigue [2%]).<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (92%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (77%), vomiting (46%), constipation (40%), diarrhea (34%), abdominal pain (32%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia/fatigue (77%), pyrexia (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (74%), increased AST (73%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (67%), decreased lymphocytes (45%), anemia (44%), decreased platelets (39%), decreased absolute neutrophil count (35%), thrombocytopenia (21%), neutropenia (15%)</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (39%), increased cholesterol (40%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (39%), dizziness (17%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (21%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Dermatitis/Rash (13%), photosensitivity reaction (10%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, palmar-plantar erythrodysesthesia syndrome<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Myelodysplastic syndrome, acute myeloid leukemia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Rubraca (rucaparib)." Clovis Oncology Inc, Boulder, CO. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of cancer is Rubraca used to treat?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about rucaparib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: PARP inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Rucaparib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Rubraca</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Ovarian Cancer</li>
<li>Prostate Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rucaparib: oral tablet</i></p><h3>General</h3><p>-The most common adverse reactions reported in at least 20% of patients were nausea, asthenia/fatigue, vomiting, anemia, constipation, dysgeusia, decreased appetite, diarrhea, abdominal pain, dyspnea, and thrombocytopenia.</p><p>-The most common laboratory abnormalities reported in at least 35% of patients were increased creatinine, increased ALT, increased AST, decreased hemoglobin, decreased lymphocytes, increased cholesterol, decreased platelets, and decreased absolute neutrophil count.</p><p>-Adverse reactions led to dose reduction or interruption in 62% of patients (most frequently from anemia [27%] and asthenia/fatigue [22%]), and to dose discontinuation in 10% of patients (most frequently from asthenia/fatigue [2%]).<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (92%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (77%), vomiting (46%), constipation (40%), diarrhea (34%), abdominal pain (32%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia/fatigue (77%), pyrexia (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (74%), increased AST (73%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (67%), decreased lymphocytes (45%), anemia (44%), decreased platelets (39%), decreased absolute neutrophil count (35%), thrombocytopenia (21%), neutropenia (15%)</p><p><b>Common</b> (1% to 10%): Febrile neutropenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (39%), increased cholesterol (40%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (39%), dizziness (17%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (21%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Dermatitis/Rash (13%), photosensitivity reaction (10%)</p><p><b>Common</b> (1% to 10%): Pruritus, palmar-plantar erythrodysesthesia syndrome<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Myelodysplastic syndrome, acute myeloid leukemia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Rubraca (rucaparib)." Clovis Oncology Inc, Boulder, CO. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of cancer is Rubraca used to treat?</li>
</ul><h2>More about rucaparib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: PARP inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Rucaparib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Ovarian Cancer</li>
<li>Prostate Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>